Invasive Aspergillosis Clinical Pipeline | 3+ Innovators, Including F2G, Cellix Bio, and SCYNEXIS, Advancing the Next Wave of Breakthrough Therapies

The Invasive Aspergillosis market is rapidly advancing with groundbreaking research and innovative therapies, driving new hope for improved treatment outcomes.

DelveInsight's 'Invasive Aspergillosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Invasive Aspergillosis therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Invasive Aspergillosis pipeline domain.

For Invasive Aspergillosis emerging drugs, the Invasive Aspergillosis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Invasive Aspergillosis Pipeline Report
• DelveInsight's Invasive Aspergillosis Pipeline analysis depicts a robust space with 3+ active players working to develop 3+ pipeline drugs for Invasive Aspergillosis treatment.
• The leading Invasive Aspergillosis companies include F2G Biotech GmbH, CSPC Ouyi Pharmaceutical Co., Ltd., Regeneron/Sanofi, Pulmocide, Astellas Pharma, Cipla/Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF Pharmaceuticals, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, ImmuPharma, Takis, and others are evaluating their lead assets to improve the Invasive Aspergillosis treatment landscape.
• Key Invasive Aspergillosis pipeline therapies in various stages of development include Olorofim, AmBisome, Amphotericin B cholesteryl sulfate complex for injection, Dupilumab, PC945, Isavuconazole, Itraconazole inhaled, CLX-PUL-597E, Ibrexafungerp, TFF VORI, MAT2203, APX 2041, Rezafungin acetate, BioAMP B, Trazimab, and others, and others.
• In March 2024, Astellas' Cresemba (isavuconazonium sulfate) received FDA orphan drug exclusivity and pediatric market exclusivity for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM).
• In December 2023, Astellas Pharma announced that the FDA had approved CRESEMBA Registered (isavuconazonium sulfate), an azole antifungal, for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients.

Request a sample and discover the recent breakthroughs happening in the Invasive Aspergillosis pipeline landscape @ https://www.delveinsight.com/report-store/invasive-aspergillosis-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Invasive Aspergillosis Overview
Invasive aspergillosis is the most prevalent mold infection in immunocompromised individuals, caused by the ubiquitous hyaline mold Aspergillus. While exposure to Aspergillus conidia is common, invasive disease rarely occurs in immunocompetent hosts due to effective immune control. Key risk factors for infection include neutropenia and glucocorticoid use, along with hematopoietic cell transplantation, solid organ transplantation (especially lung transplantation), biological therapies, pulmonary conditions, and critical illness.

The most frequently implicated species is Aspergillus fumigatus complex, though other common pathogens include A. flavus, A. terreus, and A. niger. Additionally, rarer species such as A. nidulans, A. calidoustus, and A. lentulus have been observed in severely immunosuppressed patients. These "cryptic" species, often challenging to identify, are clinically significant due to their varied antifungal resistance profiles. Effective management of invasive aspergillosis involves preventive measures, rapid diagnosis, timely antifungal therapy, and, in certain cases, immunomodulation and surgical intervention. Notably, an increasing number of invasive aspergillosis cases have emerged as complications of COVID-19 infection.

Find out more about Invasive Aspergillosis medication @ https://www.delveinsight.com/report-store/invasive-aspergillosis-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Invasive Aspergillosis Treatment Analysis: Drug Profile
Olorofim: F2G
Olorofim (formerly F901318) is F2G's leading candidate from this class and has fungicidal activity against a broad range of mould infections including a variety of rare and resistant moulds that cause life-threatening infections for which current therapies have limitations or are ineffective. Olorofim has received orphan drug status from the European Medicines Agency and orphan drug status, Qualified Infectious Disease Product (QIDP) designation and Breakthrough Therapy designation from FDA.

Ibrexafungerp: SCYNEXIS
Ibrexafungerp (formerly SCY-078) is the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. It has shown activity against Aspergillus and Candida, including against multidrug-resistant (MDR) species Candida auris as well as Pneumocystis. Ibrexafungerp combines the well-established activity of glucan synthase inhibitors with the flexibility of oral and IV formulations, offering a broad use across different settings (in-patient and out-patient).

Key Invasive Aspergillosis Therapies and Companies
• Olorofim: Shionogi & Co., Ltd. and F2G Ltd.
• AmBisome: Gilead Sciences
• Amphotericin B cholesteryl sulfate complex for injection: ALZA
• Dupilumab - Regeneron/Sanofi
• PC945: Pulmocide
• Isavuconazole: Basilea Pharmaceutica
• Itraconazole inhaled - Cipla/Pulmatrix
• Ibrexafungerp - SCYNEXIS
• MAT2203: Matinas BioPharma
• Trazimab - Takis

Learn more about the novel and emerging Invasive Aspergillosis pipeline therapies @ https://www.delveinsight.com/report-store/invasive-aspergillosis-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Invasive Aspergillosis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

By Molecule Type
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Scope of the Invasive Aspergillosis Pipeline Report
• Coverage: Global
• Key Invasive Aspergillosis Companies: F2G Biotech GmbH, CSPC Ouyi Pharmaceutical Co., Ltd., Regeneron/Sanofi, Pulmocide, Astellas Pharma, Cipla/Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF Pharmaceuticals, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, ImmuPharma, Takis, and others.
• Key Invasive Aspergillosis Pipeline Therapies: Olorofim, AmBisome, Amphotericin B cholesteryl sulfate complex for injection, Dupilumab, PC945, Isavuconazole, Itraconazole inhaled, CLX-PUL-597E, Ibrexafungerp, TFF VORI, MAT2203, APX 2041, Rezafungin acetate, BioAMP B, Trazimab, and others, and others.

Dive deep into rich insights for drugs used for Invasive Aspergillosis treatment; visit @ https://www.delveinsight.com/report-store/invasive-aspergillosis-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Invasive Aspergillosis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Invasive Aspergillosis Pipeline Therapeutics
6. Invasive Aspergillosis Pipeline: Late-Stage Products (Phase III)
7. Invasive Aspergillosis Pipeline: Late-Stage Products (Phase III)
8. Invasive Aspergillosis Pipeline: Mid-Stage Products (Phase II)
9. Invasive Aspergillosis Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.